Using Selection Model for Missing Data in Comparing Degeneration Patients in Combination with Triamcinolone Clinical Trial in Age-related Macular Intravitreal Bevacizumab Injection Alone and

In the study، the intravitreal bevacizumab injection treatment alone and in combination with triamcinolone، acco-rding to the data obtained from a rando-mized clinical trial using selection model for informative missingness، were comp-ared. In the current study، the modeling was executed on 90 patients with age-related macular degeneration (AMD) having a variety of choroidal neovascularization (CNV) lesions. They had not got any treatment before the beginning of the clinical trials. The patients were randomly assigned into two groups: Intravitreal bevacizumab injection alone and in combination with triamcinolone. To compare the effects of these treatments on these patients، the selection model (for informative missingness) was fitted with the elimination of other covariates. Two major outcomes investigated in this study، were the variation of best-corrected visual acuity (BCVA) and variation of central macular thickness (CMT). The results of selection model for informative missingness revealed that the reduction in CMT in intravitreal bevaciz-umab injection combined with triamcino-lone was more significant than its reduction in intravitreal bevacizumab injection alone (P=0. 026). Discussion & In patients with neovascular AMD، intravitreal bevacizum-ab injection in combination with triamcino-lone significantly leads to better BCVA and lower CMT than intravitreal bevacizumab injection alone.